Kira Biotech
Kira Biotech is an Australian biotechnology company focused on developing novel immunomodulatory drugs for the treatment of immune system disorders. Its mission is to develop therapies that restore immune homeostasis and tolerance, with a team led by experienced drug development experts. The company has attracted venture capital funding and is advancing its lead candidate, KB312, through preclinical and phase 1 trials.
Industries
Nr. of Employees
small (1-50)
Kira Biotech
Level 3, 88 Jephson Street, Toowong, QLD, 4066
Patents
Products
KB312
A selective immune-cell depleting monoclonal antibody candidate designed to target activated immune cells and induce immune tolerance; described as the company's lead candidate in preclinical development and progressing to Phase 1 clinical trials.
KB312
A selective immune-cell depleting monoclonal antibody candidate designed to target activated immune cells and induce immune tolerance; described as the company's lead candidate in preclinical development and progressing to Phase 1 clinical trials.
Services
End-to-end advancement of immunomodulatory monoclonal antibody candidates from discovery and preclinical studies through early clinical development.
Operational support for program leadership, alliance management, procurement and vendor coordination to enable milestone-driven development.
End-to-end advancement of immunomodulatory monoclonal antibody candidates from discovery and preclinical studies through early clinical development.
Operational support for program leadership, alliance management, procurement and vendor coordination to enable milestone-driven development.
Expertise Areas
- Therapeutic antibody development
- Immunology and rheumatology therapeutics
- Preclinical development for biologics
- Early-phase clinical trial management (Phase 1)
Key Technologies
- Monoclonal antibodies
- Immunomodulatory biologics
- Immune-cell depletion approaches
- Induction of immune tolerance
News & Updates
Announcement of Kira Biotech's launch with Series A funding of A$20 million.
Announcement of Kira Biotech's launch with Series A funding of A$20 million.